عرض مصدر نقاش القالب:خافضات السكر الفموية ومشابهات الإنسولين

== نسخة قالب مكررة ==
{{Navbox
| name  = Oral hypoglycemics and insulin analogs
| title = أدوية فموية خافضة لسكر الدم ومضاهيات الإنسولين (A10)
Oral [[anti-diabetic drug]]s and [[Insulin analog]]s ([[ATC code A10|A10]]) [http://en.wikipedia.org/wiki/Template:Oral_hypoglycemics_and_insulin_analogs القالب الإنكليزي]
| listclass = hlist
| groupstyle = background:#fd6;

|group1  = [[Insulin]]
|list1   = {{Navbox subgroup
  | groupstyle = background:#fd6;

 | group1 = [[anti-diabetic drug#Sensitizers|Sensitizers]]
 |  list1 = {{Navbox subgroup
  | groupstyle = background:#fd6;

  | group1 = [[Biguanide]]s
  |  list1 =
* [[Metformin]]<sup>#</sup>
* [[Buformin]]<sup>‡</sup>
* [[Phenformin]]<sup>‡</sup>

  | group2 = [[Thiazolidinedione|TZD]]s ([[PPAR modulator|PPAR]])
  |  list2 =
* [[Pioglitazone]]
* [[Rivoglitazone]]<sup>†</sup>
* [[Rosiglitazone]]
* [[Troglitazone]]<sup>‡</sup>

  | group3 = [[PPAR_modulator#Dual-PPAR_modulators|Dual PPAR agonist]]
  |  list3 =
* [[Aleglitazar]]<sup>†</sup>
* [[Muraglitazar]]<sup>§</sup>
* [[Tesaglitazar]]<sup>§</sup>
}}

| group2 = [[anti-diabetic drug#Secretagogues|Secretagogues]]
|  list2 = {{Navbox subgroup
  | groupstyle = background:#fd6;

  | group1 = [[ATP-sensitive potassium channel|K+ ATP]]
  |  list1 = {{Navbox subgroup
  | groupstyle = background:#fd6;

| group1 = [[Sulfonylurea]]s
| list1  =
* ''[[Sulfonylurea#First generation|1st generation]]'': [[Acetohexamide]]
* [[Carbutamide]]
* [[Chlorpropamide]]
* [[Metahexamide]]
* [[Tolbutamide]]
* [[Tolazamide]]

''[[Sulfonylurea#Second generation|2nd generation]]'': [[Glibenclamide|Glibenclamide (Glyburide)]]<sup>#</sup>
* [[Glibornuride]]
* [[Glipizide]]
* [[Gliquidone]]
* [[Glisoxepide]]
* [[Glyclopyramide]] 
* [[Glimepiride]] 
* [[Gliclazide]]

| group2 = [[Meglitinide]]s/"glinides" 
|  list2 =
* [[Nateglinide]]
* [[Repaglinide]]
* [[Mitiglinide]]

}} 

| group3 = [[Glucagon-like peptide-1 analog|GLP-1 analogs]]
|  list3 =
* [[Exenatide]]
* [[Liraglutide]]
* [[Taspoglutide]]<sup>†</sup>
* [[Albiglutide]]<sup>†</sup>
* [[Lixisenatide]]

  | group4 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s
  |  list4 =
* [[Alogliptin]]<sup>†</sup>
* [[Gemigliptin]]
* [[Linagliptin]]
* [[Saxagliptin]]
* [[Sitagliptin]]
* [[Vildagliptin]]

}}

| group3 = [[Insulin analog|Analog]]s/other insulins
|  list3 =
* ''fast-acting'' ([[Insulin lispro]]
* [[Insulin aspart]]
* [[Insulin glulisine]])
* '' short-acting'' ([[Insulin therapy|Regular insulin]])
* ''long-acting'' ([[Insulin glargine]]
* [[Insulin detemir]]
* [[NPH insulin]])
* ''ultra-long-acting'' ([[Insulin degludec]]<sup>†</sup>)
* ''inhalable'' [[Inhalable insulin|Exubera]]<sup>‡</sup>

}}

| group10 = Other
|  list10 = {{Navbox subgroup
  | groupstyle = background:#fd6;

| group3 = [[Alpha-glucosidase inhibitor]]s
|  list3 =
* [[Acarbose]]
* [[Miglitol]]
* [[Voglibose]]

  | group8 = [[Amylin]] analog
  |  list8 =
* [[Pramlintide]]

  | group11 = [[Sodium-glucose transport proteins|SGLT2]] inhibitors
  |  list11 =
* [[Canagliflozin]]<sup>†</sup>
* [[Dapagliflozin]]<sup>†</sup>
* [[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup>
* [[Sergliflozin etabonate|Sergliflozin]]<sup>§</sup>

  | group12 = Other
  |  list12 =
* [[Benfluorex]]<sup>‡</sup>
* [[Tolrestat]]<sup>‡</sup>

}}

| list11 = {{PharmNavFootnote}}

| belowstyle = background: transparent; padding: 0px;
| below = {{Endocrine navs}}

}}